Dr. Slaoui left GlaxoSmithKline in 2017 and has worked as a venture capitalist since. In his role as therapeutics czar, he will help coordinate the development of COVID-19 vaccines and treatments.
The position is part of a program the White House calls Operation Warp Speed, designed to drastically cut the time needed to develop a COVID-19 vaccine.
Dr. Slaoui also sits on the board of Moderna, a drugmaker developing a COVID-19 vaccine, Politico reported. His role as therapeutics czar will be split between HHS and the U.S. Defense Department.
Read the full article here.
More articles on pharmacy:
32 of 40 drugs deemed critical for COVID-19 in short supply
Gilead strikes deal to manufacture remdesivir for 127 countries
How Civica Rx has responded to drug shortages caused by COVID-19
